<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04892186</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE: 23458719.6.0000.0068</org_study_id>
    <nct_id>NCT04892186</nct_id>
  </id_info>
  <brief_title>Effects of Myo-inositol in Women With Polycystic Ovary Syndrome</brief_title>
  <official_title>Effects of Myo-inositol on the Menstrual Cycle, Hyperandrogenism, Chronic Inflammatory Process and Carbohydrate Metabolism in Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be carried out at the hospital of the medical school of sao paulo (HC-FMUSP)&#xD;
      and the goal is to compare the effects of the administration of myo-inositol in relation to&#xD;
      the effects of metformin in women with Polycystic Ovary Syndrome and insulin resistance or&#xD;
      glucose intolerance. Menstrual cycle, hyperandrogenism, chronic inflammatory process,&#xD;
      carbohydrate metabolism, hepatic steatosis will be evaluated. In total, 60 women in the&#xD;
      reproductive period, with a variable age between 18 and 36 years old will be recruited and&#xD;
      randomized in two groups: intervention- myo-inositol for 6 months, control group will use&#xD;
      metformin also for 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will involve 60 women in the reproductive period, with a variable between 18 and 36&#xD;
      years old and diagnosed with polycystic ovary syndrome (PCOS), according to Rotterdam-&#xD;
      European Society of Human Reproduction and Embryology (ESHRE) / American Society for&#xD;
      Reproductive Medicine (ASRM) criteria defined in 2003 and by the entity The Androgen Excess&#xD;
      and Polycystic Ovary Syndrome Society (AE-PCOS) 2018, and insulin resistance (presence&#xD;
      acanthosis nigricans) or glucose intolerance (fasting glycemia, glycated hemoglobin or 75g&#xD;
      glycemic overload and blood glucose assessment after 2 hours). It is a comparative and&#xD;
      non-inferiority study of myo-inositol in relation to metformin. They will be divided into two&#xD;
      groups of 30 patients: Group I (control) - they will receive metformin, orally, three times a&#xD;
      day; Group II (experiment) - they will receive myo-inositol 2g, orally, twice a day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 20, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Comparative and non-inferiority study of myo-inositol in relation to metformin. They will be divided into two groups of 30 patients: Group I (control) - they will receive metformin, orally, three times a day; Group II (experiment) - they will receive myo-inositol 2g, orally, twice a day.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Menstrual cycle</measure>
    <time_frame>6 months</time_frame>
    <description>Analysis of period calendar.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glucose metabolism</measure>
    <time_frame>Every 3 months for up to 6 months</time_frame>
    <description>Glucose tolerance curve with insulin curve will be performed every 3 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glycated hemoglobin</measure>
    <time_frame>Every 3 months for up to 6 months</time_frame>
    <description>Glycated hemoglobin will be performed every 3 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ultrasound of the ovaries</measure>
    <time_frame>6 months</time_frame>
    <description>Transvaginal ultrasound to assess ovarian volume (measured in cubic centimeters) will be done before and after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in antral follicle count</measure>
    <time_frame>6 months</time_frame>
    <description>Ultrasound of the ovaries will be done before and after treatment for antral follicle count (all follicles from 2 to 9 mm will be measured)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in body mass index</measure>
    <time_frame>Every 3 months for up to 6 months</time_frame>
    <description>Body mass index (kg/m2) will be assessed every 3 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Abdominal Circumference and Hip Circumference</measure>
    <time_frame>Every 3 months for up to 6 months</time_frame>
    <description>Abdominal circumference and hip circumference (measured in centimeters) will be assessed every 3 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in body weight in kilograms</measure>
    <time_frame>Every 3 months for up to 6 months</time_frame>
    <description>Patients will be weighed every 3 months (measured in kilograms).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess adherence to treatment.</measure>
    <time_frame>Every 3 months for up to 6 months</time_frame>
    <description>Medication use diary will be delivered and will be reviewed every 3 months to assess adherence to treatment (good adherence will be considered use of more than 80% of the medication provided).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Every 3 months for up to 6 months</time_frame>
    <description>Questionnaire will be carried out every 3 months for patient to describe the 3 main side effects and how much they have hindered the treatment or not.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic steatosis</measure>
    <time_frame>6 months</time_frame>
    <description>Initial liver ultrasound will be done and repeated after 6 months of treatment to assess the presence or absence of hepatic steatosis and classify it as mild (grade 1), moderate (grade 2) and severe (grade 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzymes</measure>
    <time_frame>6 months</time_frame>
    <description>Liver enzymes (aspartate aminotransferase, alanine aminotransferase,alkaline phosphatase) will be collected before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic inflammatory process</measure>
    <time_frame>6 months</time_frame>
    <description>Chronic inflammatory markers will be accessed by analyzing RNA messenger from cervical-vaginal cytology before and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>6 months</time_frame>
    <description>Chronic inflammatory process will be also evaluated by serum measurement of c-reactive protein before and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homocysteine</measure>
    <time_frame>6 months</time_frame>
    <description>Serum homocysteine dosage will be done before and after treatment to help assess a chronic inflammatory process.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lipid Profile</measure>
    <time_frame>Every 3 months for up to 6 months</time_frame>
    <description>Serum dosage of the lipid profile (high density lipoprotein - HDL, low density lipoprotein - LDL , very low density lipoprotein - VLDL, triglycerides, total cholesterol) will be done every 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Ferriman-Gallwey Score</measure>
    <time_frame>6 months</time_frame>
    <description>Modified Ferriman-Gallwey Score will be performed before and after treatment and patients with a score above 7 will be considered hirsute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal dosage (FSH, LH, progesterone, estradiol)</measure>
    <time_frame>6 months</time_frame>
    <description>Hormonal dosage (FSH - Follicle-stimulating hormone, LH - luteinizing hormone, progesterone, estradiol) will be preformed before and after treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Resistance, Insulin</condition>
  <condition>Glucose Intolerance</condition>
  <arm_group>
    <arm_group_label>Myo-inositol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 women with resistance insulin or glucose intolerance will receive myo-inositol 2g, orally, twice a day for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 women with resistance insulin or glucose intolerance will receive metformin, orally, three times a day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myo-inositol</intervention_name>
    <description>30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used myo-inositol 2g twice daily for 6 months, having a re-evaluation every 3 months.&#xD;
Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference.</description>
    <arm_group_label>Myo-inositol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used metformin three times a day for 6 months, having a re-evaluation every 3 months.&#xD;
Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference.</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged 18 to 36 with diagnosis of PCOS and insulin resistance or glucose&#xD;
             intolerance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous use of any hormonal treatment in the past three months;&#xD;
&#xD;
          -  Other causes of anovulation;&#xD;
&#xD;
          -  Gynecological or other associated conditions (endometriosis, adenomyosis or diabetes&#xD;
             mellitus);&#xD;
&#xD;
          -  FSH (Follicle Stimulating Hormone) &gt; 15 Ul / L (2nd to 5th day of the cycle);&#xD;
&#xD;
          -  Beta-hcG (human chorionic gonadotropin) positive (pregnancy).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edmund Chada Baracat, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>research coordinator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose Maria Soares, Phd</last_name>
    <phone>551126617621</phone>
    <email>jsoares415@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lorena Urbanetz, MD</last_name>
    <phone>5511949874080</phone>
    <email>lourbanetz@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Das Clinicas - Fmusp</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Urbanetz, MD</last_name>
      <phone>5511949874080</phone>
      <email>lourbanetz@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose M Soares Junior, PhD</last_name>
      <phone>551126617621</phone>
      <email>jsoares415@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>May 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myo-inositol</keyword>
  <keyword>metformin</keyword>
  <keyword>polycystic ovary syndrome</keyword>
  <keyword>resistance insulin</keyword>
  <keyword>glucose intolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inositol</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

